<DOC>
	<DOCNO>NCT02200614</DOCNO>
	<brief_summary>The purpose study assess safety efficacy BAY1841788 ( ODM-201 ) patient non-metastatic castration-resistant prostate cancer .</brief_summary>
	<brief_title>Efficacy Safety Study BAY1841788 ( ODM-201 ) Men With High-risk Non-metastatic Castration-resistant Prostate Cancer ( ARAMIS )</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Histologically cytologically confirm adenocarcinoma prostate without neuroendocrine differentiation small cell feature . Castrationresistant prostate cancer ( CRPC ) castrate level serum testosterone . Prostatespecific antigen double time ≤ 10 month PSA &gt; 2ng/ml . Eastern Cooperative Oncology Group ( ECOG ) performance status 01 . Blood count screen : haemoglobin ≥ 9.0 g/dl , absolute neutrophil count ≥ 1500/µl , platelet count ≥ 100,000/µl . Screening value serum alanine aminotransferase ( ALT ) and/or aspartate transaminase ( AST ) ≤ 2.5 x upper limit normal ( ULN ) , total bilirubin ≤ 1.5 x ULN , creatinine ≤ 2.0 x ULN . Sexually active patient , unless surgically sterile , must agree use condom effective barrier method refrain sperm donation study treatment 3 month end study treatment . History metastatic disease time presence detectable metastasis . Acute toxicities prior treatment procedures resolve grade ≤ 1 baseline randomisation . Prior treatment : second generation androgen receptor ( AR ) inhibitor , investigational AR inhibitor , CYP17 enzyme inhibitor . Use estrogens 5α reductase inhibitor AR inhibitor . Prior chemotherapy immunotherapy prostate cancer . Use systemic corticosteroid . Radiation therapy within 12 week randomisation . Severe uncontrolled concurrent disease , infection comorbidity . Treatment bisphosphonate denosumab within 12 week randomisation . Known hypersensitivity study treatment ingredient . Major surgery within 28 day randomisation . Any follow within 6 month randomisation : stroke , myocardial infarction , severe/unstable angina pectoris , coronary/peripheral artery bypass graft ; congestive heart failure New York Heart Association ( NYHA ) Class III IV . Uncontrolled hypertension . Prior malignancy . Gastrointestinal disorder procedure expect interfere significantly absorption study treatment . Active viral hepatitis , active human immunodeficiency virus ( HIV ) chronic liver disease . Treatment investigational drug within 28 day randomisation . Any condition opinion investigator would impair patient ' ability comply study procedure .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>